- Home
- HG vs IBRX Comparison
HG vs IBRX Comparison
Compare HG & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | IBRX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | HG | IBRX |
|---|---|---|
| Price | $28.14 | $2.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $29.00 | $9.71 |
| AVG Volume (30 Days) | 434.6K | ★ 14.9M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.19 | N/A |
| Revenue | ★ $2,745,461,000.00 | $82,555,000.00 |
| Revenue This Year | $25.41 | $667.18 |
| Revenue Next Year | $0.82 | $93.03 |
| P/E Ratio | $6.77 | ★ N/A |
| Revenue Growth | 21.12 | ★ 1025.95 |
| 52 Week Low | $16.80 | $1.83 |
| 52 Week High | $28.72 | $4.27 |
Technical Indicators
Market Signals| Indicator | HG | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 47.16 |
| Support Level | $27.45 | $2.07 |
| Resistance Level | $28.72 | $2.29 |
| Average True Range (ATR) | 0.53 | 0.13 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 73.35 | 27.00 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.